Approved by MOG: Via Monthly Medicines Optimisation Group Meetings
Ruxolitinib (INC424) Incyte® |
Formulary
|
Approved for 2nd line compassionate treatment in patients with high risk myelofibrosis (Cons. Haematologist) |
|
Sativex “Cannabis Extract” |
Formulary
|
For muscle spasticity, to be funded by Neurosciences directorate |
|